FDA OKs silver-coated breathing tube

Nov 08, 2007

The U.S. Food and Drug Administration has approved for marketing a breathing tube coated with silver to be used by patients on ventilators.

FDA officials said the thin silver coating is known to have antimicrobial properties, thereby reducing the risk that patients on ventilators will acquire pneumonia while in the hospital.

The Agento endotracheal tube is intended for patients who must rely on a ventilator to breathe for 24 hours or more. Such patients are at risk of exposure to hospital-acquired bacteria that can accumulate on the tube or pass through the tube into their lungs, eventually causing a lung infection known as ventilator-associated pneumonia, the FDA said.

Fifteen percent of the patients on ventilators develop VAP every year and 26,000 die from the infection, according to the Centers for Disease Control and Prevention.

The device is manufactured by C.R. Bard Inc. of Murray Hill, N.J.

Copyright 2007 by United Press International

Explore further: Allergan to cut 1,500 employees in restructuring (Update)

add to favorites email to friend print save as pdf

Related Stories

Checklist cuts lethal ventilator-associated lung infections

Feb 17, 2011

the most lethal and among the most common of all hospital-associated infections — dropped by more than 70 percent in Michigan hospitals where medical staff used a simple checklist designed by Johns Hopkins researchers. ...

Recommended for you

Face transplants change lives, identity

10 hours ago

Patients are prepared to take significant risks in order to be considered for a face transplant, says Dr David Koppel, director of the largest craniofacial unit in the UK and Honorary Clinical Associate Professor ...

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

User comments : 0